TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Earlier Diagnosis of RA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reduction of MRD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of meaningful breathlessness relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Effect on parasites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of participants with clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional communicative ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Identification of bacteria in the gut and oral microbiomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Patients Able to Return to Sport After Surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Stent Expansion in the side branch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average Mean Dose to 90% of DIL Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive symptoms at end of treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Relapse rates at 6 months follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Change in % Polymorphonuclear Leukocytes (PMN) in Nasal Lavage Fluid Immediately Post-Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in % Polymorphonuclear Leukocytes (PMN) in Nasal Lavage Fluid 24 Hours Post-Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fetal heart movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Maximal force of detrusor contraction (Pdet)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Evidence of Bone metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progressive disease-free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GERD symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal artery blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Recovery from tendon injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Recurrence within 1 year of treatment
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of Candidemia
Endpoint domain: Adverse events/effects
Primary endpoint: Incident tuberculosis
Endpoint domain: Mortality/survival
Primary endpoint: ApoB/ApoA ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiovascular events associated with heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: successful nNO measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Imaged Sites Correctly Categorized as Squamous Mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Imaged Sites Correctly Categorized as Barrett's Mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in baseline suicidal ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety and tolerability of Proxinium
Endpoint domain: Adverse events/effects
Primary endpoint: Streptococcus mutans levels in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Streptococcus mutans levels in tooth biofilm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyad Congruence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient's satisfaction degree
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Progressive Supranuclear Palsy Rating Scale (PSPRS) at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) and Adverse Events (AEs) Leading to Discontinuation of Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Glucose metabolic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sit and Reach test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AKE Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue scale (VAS) score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Pain Verbal Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Cerebral Blood Volume (CBV) measured by fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Modified Benton Visual Retention Test (ModBent) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of Radiation-Induced CD8 T-Lymphocyte Apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sharp Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of subjects achieving a clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chlorhexidine skin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malignancy-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Complete Aneurysm Occlusion Without Significant Parent Artery Stenosis or Prior Retreatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Neurological Death or Major Ipsilateral Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of uterine bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of i-ACT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Credibility/expectancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lumbar Puncture Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Major Adverse Clinical Events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic Behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of erlotinib hydrochloride combined with cetuximab
Endpoint domain: Adverse events/effects
Primary endpoint: MTD of bevacizumab combined with cetuximab and erlotinib hydrochloride
Endpoint domain: Adverse events/effects
Primary endpoint: Change in breath hold index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Emergence of colonisation or infection with C. difficile and/or Enterobacteriaceae resistant to 3rd generation cephalosporins
Endpoint domain: Adverse events/effects
Primary endpoint: End-expiratory lung volume:total lung capacity (EELV/TLC) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in high sensitive troponin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: preservation of an intact larynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immune responses to vaccine antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Box & Blocks Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burn Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gain in exercise tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eyeball structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss of at least 5% at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Within-tester repeatability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Between-tester reproducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-centredness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety and tolerability of montelukast oral granules
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiac geometric parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean modifications of the maximal visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of intra-vitreous injections of bevacizumab (IVIB)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of non-severe adverse events (NSAE)
Endpoint domain: Adverse events/effects
Primary endpoint: number of severe adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Global sum score of dry eye symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Time for Dissection of the Soft Tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Versatility Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of CD8+ T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in clock gene & associated omic circadian rhythms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Plasma Concentration of Lumacaftor and Ivacaftor at Hour 4 Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUCtau) of Lumacaftor and Ivacaftor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Finger temperature measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laser doppler imaging of the hands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Main index of pharmacodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Interoperator and Intraoperator Agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Who Achieve Complete Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value for one year mortality
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity for one year mortality
Endpoint domain: Mortality/survival
Primary endpoint: Sequence of microRNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in self-reported HbA1C level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neuropathic Pain Questionnaire (NPQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Methemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tissue drug levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue phospho-AKT level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability/Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients receiving plerixafor outside label indication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recurrent intussusception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area under the concentration-time curve/maximum concentration (AUC/Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients developing symptomatic brain metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Participants Achieving Clinical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Centered Outcomes questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement of Surgical Scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Systolic and Diastolic Blood Pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time until remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Daily OFF Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for Lofexidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax for Lofexidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for Lofexidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for Naltrexone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for Naltrexone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax for Naltrexone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Satisfying the 'no Re-fit' Criteria in Both Eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hazard of Progression
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Optimal Antibiotic Chosen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence rate
Endpoint domain: Adverse events/effects
Primary endpoint: Total Serous Drainage (mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of Skin Necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Congestion index on Day 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity/mortality
Endpoint domain: Mortality/survival
Primary endpoint: Enhanced activity of oral bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Enhanced cardiovascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HRQOL urinary irritative score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient comfort after surgery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dressing integrity after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between Gated SPECT Perfusion Data and Fractional Flow Reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Deep Response Rate (DRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMax in Polyphenol Anthocyanin Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased independence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of Participants With Graft Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of microbes present on skin after exposure to various surfactants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from Baseline on PTSD Checklist for DSM-5 (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline on Personal Health Questionnaire Depression Scale (PHQ - 8)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline on Difficulties in Emotion Regulation Scale - 16 item version (DERS-16)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline on The Work and Social Adjustment Scale (WSAS)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Gene expression differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calculated Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Outcome of applying IGRT to PBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified AIMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS items 32 & 33
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in antibody responses to PCV13
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Central Arterial Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of amoxicillin dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change from baseline child posttraumatic stress symptoms at posttreatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline child posttraumatic stress symptoms at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuation in treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Able to Use VR Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration and total amount of serum and GCF VCAM-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration and total amount of Neopterin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Bioavailability of Epinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal Amyloid Index (RAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Donor Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rates after conization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in self-reported negative affect and positive affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analog Scale - Head Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale - Disequilibrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: analgesic efficacy for post operative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short term impact on quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Short term impact on pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short term impact of patient function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tinnitus severity questionnaire score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of actionable mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reach of intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in self-management skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: prevalence of molar incisor hypomineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: International Physical Activity Questionnaire Short Form
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual Analog Scale for the Evaluation of Pain and Fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p16 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Average Daily Total Combined Score (TCS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in the Number of Moderate-to-Severe Headache Days Per Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Accurate BGMS Fingerstick Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in participant preference for adjuvant radiation treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in surgeon preference for adjuvant radiation treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status